ASH 2022 Conference Coverage
ASH 2022 Phase 1 MagnetisMM-1 Trial: Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical & Molecular Responses for Patients With R/R MM
By
ASH 2022 Conference Coverage
FEATURING
Noopur S. Raje
By
ASH 2022 Conference Coverage
FEATURING
Noopur S. Raje
Login to view comments.
Click here to Login